Searchable abstracts of presentations at key conferences in endocrinology

ea0086p188 | Bone and Calcium | SFEBES2022

Severe symptomatic and treatment resistant hypercalcaemia caused by a parathyroid adenoma

Javid Pernia , Lam George , Kurera Isuri

A 74 year-old woman had 4 presentations to the hospital with severe symptomatic hypercalcemia despite intensive medical therapy. She had a background of right hemithyroidectomy, hypothyroidism and rheumatoid arthritis. She first presented with symptoms of muscle weakness, vomiting, confusion and muscle aches. Her initial test results showed an adjusted calcium level of 3.79 mmol/l and PTH of 28.1 pmol/l; she was treated with IV fluids, Pamidronate 60 mg and discharged home wit...

ea0003p176 | Growth and Development | BES2002

Growth hormone replacement: Patients' views

Carson M , Perrin P , Wass J

AIMS: The Pituitary Foundation (a national UK Support Group)undertook a questionnaire of its members to solicit patients' views on their experience of growth hormone replacement (GHR). This resulted in a lay submission to NICE regarding GHR in adults.METHOD: A questionnaire was mailed to members known to be receiving GHR. 78% of these (303) were returned. In addition, a further 86 completed questionnaires were received following a...

ea0041ep253 | Clinical case reports - Pituitary/Adrenal | ECE2016

Adrenal insufficiency precipitated by Graves’ hyperthyroidism in a patient on megestrol acetate treatment

Garcia-Figueras Mateos Carolina , Cayon Blanco Manuel , Terron Pernia Alberto

Introduction: Megestrol acetate (MA) is commonly used to promote weight gain in patients with HIV infection. Adrenal insufficiency (AI) has been reported as an adverse effect of MA but this association is not frequently recognized in clinical practice and only few cases develop symptoms of AI. We describe a case of symptomatic AI precipitated by Graves’ hyperthyroidism in a HIV patient on long-term MA treatment.Case report: A 44-year-old man with HI...

ea0090ep658 | Endocrine-related Cancer | ECE2023

Clear cell renal carcinoma synchronous with various endocrine pathologies

Petria Andreea Raluca , Lazar Diana-Georgiana , Elena Oros Sabina , Ioachim Dumitru , Ionut Constantin Teodor , Grigorie Daniel

Introduction: Clear cell renal carcinoma (ccRCC) is a subtype of renal cell carcinoma, the most frequent one (80%) and usually affecting only one kidney. It is twice as common in men than women between 50 to 70 years old. It can be associated with some genetic conditions that predispose patients to ccRCC, like Von Hipple-Lindau disease. Some clinical observations and molecular studies raised the hypothesis that RCC is a hormone−dependent tumor.Case...

ea0073ep149 | Pituitary and Neuroendocrinology | ECE2021

Apparently non secreting adenoma: a new challenge

Diana-Georgiana Lazar , Elena Oros Sabina , Dumitrascu Anda , Alexandrescu Daniela , Raluca Petria Andreea , Stoica Sergiu

IntroductionSilent corticotroph adenoma represent an uncommon subtype of nonfunctioning adenoma, immunoreactive for ACTH, without clinical or biochemical evidence of hypercortisolism and unclear pathogenesis. Usually, they present with local mass effect (visual deterioration being the most common) and endocrine dysfunctions. They carry a more aggressive behavior, particularly upon earlier recurrence.Case presentation<p class="a...

ea0041ep150 | Calcium and Vitamin D metabolism | ECE2016

Vitamin D status in a HIV-infected cohort from south of Spain: descriptive analysis

Mateos Carolina Garcia-Figueras , Blanco Manuel Cayon , Herrera Patricia Bancalero , Pernia Alberto Terron

Introduction: Vitamin D deficiency is common among people living with HIV worldwide. There is a lack of studies focusing on prevalence and consequences of low levels of vitamin D in our health care area (south of Spain). The main aim of this study is to know the status of vitamin D and its consequences on parameters related to calcium metabolism in a cohort of patients with HIV infection in our area.Methods/Design: Cross-sectional study encompassing HIV-...

ea0041ep165 | Calcium and Vitamin D metabolism | ECE2016

BMI but not visceral adiposity index is related to vitamin D levels in overweight HIV-patients

Blanco Manuel Cayon , Mateos Carolina Garcia-Figueras , Herrera Patricia Bancalero , Pernia Alberto Terron

Introduction: Several studies have shown that BMI and visceral adiposity index (VAI) are inversely related to serum 25-hydroxy vitamin D (25OHD) in general population. There is a lack of studies performed in HIV population, whose body fat distribution is altered by lipodystrophy or liver disease. We aimed to analyze the cross-sectional associations of VAI and BMI with the 25OHD concentration and parameters related to calcium-phosphorus metabolism in HIV-infected patients.<...

ea0035p135 | Calcium and Vitamin D metabolism | ECE2014

Estimation of optimal serum levels of 25-hydroxyvitamin D in a cohort of HIV-infected patients

Garcia-Figueras Mateos Carolina , Blanco Manuel Cayon , Herrera Patricia Bancalero , Pernia Alberto Terron , Cortes Salvador Perez

Introduction: 25-Hydroxyvitamin D (25(OH)D) deficiency is a growing healthcare problem in HIV-infected patients. Evidence suggests that an optimal level of 25(OH)D would avoid secondary hyperparathyroidism but its optimal serum concentration has not been defined in HIV-infection. The aim of our study was to identify the 25(OH)D serum concentration that correlates to i-PTH increase and describe the prevalence of hypovitaminosis D in a cohort of HIV-infected patients.<p clas...

ea0059p085 | Diabetes &amp; cardiovascular | SFEBES2018

Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice

Dimitriadis Georgios K , Nasiri-Ansari Narjes , Agorogiannis Georgios , Perrea Despoina , Kostakis Ioannis D , Papavassiliou Athanasios G , Kaltsas Gregory , Kassi Eva , Randeva Harpal S

Sodium glucose co-transporter2 (SGLT2) inhibitors reduce the incidence of cardiovascular events in patients with Type 2 Diabetes Mellitus (T2DM) based on the results of recent cardiovascular outcome studies. Herein, we investigated the effects of long-term treatment with canagliflozin on biochemical and immunohistochemical markers related to atherosclerosis and atherosclerosis development in the aorta of Apolipoprotein E knockout (Apo-E(−/−)) mice. After...

ea0056oc10.2 | Cardiovascular aspects of endocrine diseases | ECE2018

Canagliflozin attenuates the progression of atherosclerosis via reducing hyperlipidaemia and inflammation process in ApoE KO Mice

Nasiri-Ansari Narjes , Dimitriadis Georgios K. , Agorogiannis George , Perrea Despina , Daikos George , Papavassiliou Athanasios G. , Kaltsas Gregory , Randeva Harpal S. , Kassi Eva

Introduction: Treatment with sodium glucose co-transporter2(SGLT2) inhibitors was found to reduce the incidence of cardiovascular events in diabetic patients.Herein, we investigated the effects of long-term treatment with canagliflozin on atherosclerosis development in the aorta of Apolipoprotein E knockout (Apo-E(−/−)) mice as well as on biochemical and immunohistochemical markers related to atherosclerosis.Methods: At 4 weeks of ...